BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 16182762)

  • 1. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation.
    Gruttadauria S; Vasta F; Mandalà L; Cintorino D; Piazza T; Spada M; Verzaro R; Gridelli B
    Transplant Proc; 2005; 37(6):2611-3. PubMed ID: 16182762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A safe immunosuppressive protocol in adult-to-adult living related liver transplantation.
    Gruttadauria S; Cintorino D; Piazza T; Mandala L; Doffria E; Musumeci A; Di Trapani G; Arcadipane A; Scianna G; Spada M; Verzaro R; Volpes R; Vizzini G; Palazzo U; Minervini M; Marsh JW; Marcos A; Gridelli B
    Transplant Proc; 2006 May; 38(4):1106-8. PubMed ID: 16757278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of basiliximab with a tacrolimus-based regimen in liver transplant recipients.
    Marino IR; Doria C; Scott VL; Foglieni CS; Lauro A; Piazza T; Cintorino D; Gruttadauria S
    Transplantation; 2004 Sep; 78(6):886-91. PubMed ID: 15385809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of basiliximab induction therapy in adult-to-adult living-related transplantation and deceased donor liver transplantation: a comparative retrospective analysis of a single-center series.
    Viganò J; Gruttadauria S; Mandalà L; Petridis I; Cintorino D; Li Petri S; Varotti G; Minervini M; Volpes R; Biondo D; Vizzini G; Marsh WJ; Marcos A; Gridelli B
    Transplant Proc; 2008; 40(6):1953-5. PubMed ID: 18675099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
    Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
    J Surg Res; 2007 Apr; 138(2):198-204. PubMed ID: 17292404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients.
    Calmus Y; Scheele JR; Gonzalez-Pinto I; Jaurrieta EJ; Klar E; Pageaux GP; Scudamore CH; Cuervas-Mons V; Metselaar HJ; Prestele H; Girault D
    Liver Transpl; 2002 Feb; 8(2):123-31. PubMed ID: 11862588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage.
    Liu CL; Fan ST; Lo CM; Chan SC; Ng IO; Lai CL; Wong J
    Liver Transpl; 2004 Jun; 10(6):728-33. PubMed ID: 15162466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basiliximab induction in adult liver transplant recipients with 93% rejection-free patient and graft survival at 24 months.
    Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
    Transplant Proc; 2006 Dec; 38(10):3633-5. PubMed ID: 17175352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial.
    Neuhaus P; Clavien PA; Kittur D; Salizzoni M; Rimola A; Abeywickrama K; Ortmann E; Chodoff L; Hall M; Korn A; Nashan B;
    Liver Transpl; 2002 Feb; 8(2):132-42. PubMed ID: 11862589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab.
    Sugiyama K; Isogai K; Horisawa S; Toyama A; Satoh H; Saito K; Nakagawa Y; Tasaki M; Takahashi K; Hirano T
    Cell Transplant; 2012; 21(2-3):565-70. PubMed ID: 22793066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The renal-sparing efficacy of basiliximab in adult living donor liver transplantation.
    Lin CC; Chuang FR; Lee CH; Wang CC; Chen YS; Liu YW; Jawan B; Chen CL
    Liver Transpl; 2005 Oct; 11(10):1258-64. PubMed ID: 16184544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G; Walsh G; Deshpande P; Koffman G
    Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
    Montini G; Murer L; Ghio L; Pietrobon B; Ginevri F; Ferraresso M; Cardillo M; Scalamogna M; Perfumo F; Edefonti A; Zanon GF; Zacchello G
    Transpl Int; 2005 Jan; 18(1):36-42. PubMed ID: 15612981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience.
    Lee H; Lee S; Jeon JS; Kwon SH; Noh H; Han DC; Yun S; Song D
    Transplant Proc; 2018 Jun; 50(5):1285-1288. PubMed ID: 29880348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial immunosuppression with or without basiliximab: a comparative study.
    Martín-Mateos RM; Graus J; Albillos A; Arocena C; Rodríguez Gandía MA; Blesa C; García-Hoz F; García González M; García-Alonso FJ; Bárcena R
    Transplant Proc; 2012 Nov; 44(9):2570-2. PubMed ID: 23146457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
    Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience.
    Aw MM; Taylor RM; Verma A; Parke A; Baker AJ; Hadzic D; Muiesan P; Rela M; Heaton ND; Mieli-Vergani G; Dhawan A
    Transplantation; 2003 Mar; 75(6):796-9. PubMed ID: 12660504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of Tacrolimus without Basiliximab in Well-Matched Living-Donor Renal Transplant Recipients in Korea.
    Baek CH; Kim JH; Yu H; Shin E; Cho H; Kim H; Yang WS; Han DJ; Park SK
    Exp Clin Transplant; 2016 Aug; 14(4):389-93. PubMed ID: 27228054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of basiliximab on renal allograft rejection within 1 year after transplantation.
    Lee BM; Oh CK; Jin SH; Kim JH; Kim SJ; Kim H; Shin GT
    Transplant Proc; 2006 Sep; 38(7):2025-8. PubMed ID: 16979988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Basiliximab in the treatment of acute steroid-resistant rejection after liver transplantation].
    Alvarez Castro AM; Seijo Ríos S; Molina Pérez E; Castroagudín JF; Varo Pérez E
    Gastroenterol Hepatol; 2012 Nov; 35(9):649-51. PubMed ID: 22749511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.